Literature DB >> 9184112

Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans.

G Lynch1, R Granger, J Ambros-Ingerson, C M Davis, M Kessler, R Schehr.   

Abstract

Elderly subjects (65-76 years) were tested for recall of nonsense syllables prior to and after oral administration of 1-(quinoxalin-6 ylcarbonyl)piperidine (CX516), a centrally active drug that enhances currents mediated by AMPA-type glutamate receptors. A significant and positive drug effect was found for delayed (5 min) recall at 75 min posttreatment; average scores for the highest dose group were more than twofold greater than for the placebo group. The drug had no evident influence on heart rate or self-assessment of several psychological variables.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9184112     DOI： 10.1006/exnr.1997.6447

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


  32 in total

1.  Combinatorial chemistry and high-throughput screening in drug discovery: different strategies and formats.

Authors:  P Seneci; S Miertus
Journal:  Mol Divers       Date:  2000       Impact factor: 2.943

2.  A desensitization-selective potentiator of AMPA-type glutamate receptors.

Authors:  Masayuki Sekiguchi; Kaori Nishikawa; Shunsuke Aoki; Keiji Wada
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 3.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 4.  Challenges for and current status of research into positive modulators of AMPA receptors.

Authors:  Simon E Ward; Benjamin D Bax; Mark Harries
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

5.  Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated with moderate cognitive impairment in humans.

Authors:  Ye Wu; Amy C Arai; Gavin Rumbaugh; Anand K Srivastava; Gillian Turner; Takashi Hayashi; Erika Suzuki; Yuwu Jiang; Lilei Zhang; Jayson Rodriguez; Jackie Boyle; Patrick Tarpey; F Lucy Raymond; Joke Nevelsteen; Guy Froyen; Mike Stratton; Andy Futreal; Jozef Gecz; Roger Stevenson; Charles E Schwartz; David Valle; Richard L Huganir; Tao Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-07       Impact factor: 11.205

Review 6.  Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.

Authors:  Stefano Marenco; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats.

Authors:  Sara N Burke; Andrew P Maurer; Zhiyong Yang; Zaneta Navratilova; Carol A Barnes
Journal:  Behav Neurosci       Date:  2008-06       Impact factor: 1.912

8.  High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors.

Authors:  John McNeish; Marsha Roach; John Hambor; Robert J Mather; Laura Weibley; John Lazzaro; Justin Gazard; Jacob Schwarz; Robert Volkmann; David Machacek; Steve Stice; Laura Zawadzke; Christopher O'Donnell; Raymond Hurst
Journal:  J Biol Chem       Date:  2010-03-08       Impact factor: 5.157

Review 9.  Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.

Authors:  Maria R Dauvermann; Graham Lee; Neil Dawson
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

10.  Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy.

Authors:  Jonathan E Harms; Morris Benveniste; John K F Maclean; Kathryn M Partin; Craig Jamieson
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.